Get the Stockscreener App
0.6561
4.54%
0.0285
After Hours:
.64
-0.0161
-2.45%
VolitionRX Ltd stock is traded at $0.6561, with a volume of 273.75K.
It is up +4.54% in the last 24 hours and up +4.61% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.6276
Open:
$0.66
24h Volume:
273.75K
Relative Volume:
1.23
Market Cap:
$70.59M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-1.8225
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
+8.99%
1M Performance:
+4.61%
6M Performance:
+15.92%
1Y Performance:
-6.28%
1-Day Range:
$0.625
$0.67
1-Week Range:
$0.6005
$0.67
52-Week Range:
$0.3951
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.6561 | 66.81M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
Is now a turning point for VolitionRx Limited2025 Price Targets & AI Driven Stock Movement Reports - Newser
Ranking VolitionRx Limited among high performing stocks via tools2025 Valuation Update & High Yield Stock Recommendations - Newser
How to read the order book for VolitionRx Limited2025 Buyback Activity & Target Return Focused Picks - Newser
Advanced analytics toolkit walkthrough for VolitionRx LimitedRisk Management & Community Consensus Stock Picks - Newser
D. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX) - MarketBeat
Long term hold vs stop loss in VolitionRx LimitedWeekly Loss Report & Precise Swing Trade Entry Alerts - Newser
Should you wait for a breakout in VolitionRx LimitedGap Down & Free Long-Term Investment Growth Plans - Newser
Is VolitionRx Limited stock poised for growth2025 Risk Factors & AI Enhanced Trade Execution Alerts - Newser
How to build a dashboard for VolitionRx Limited stockStop Loss & Precise Swing Trade Alerts - Newser
Will VolitionRx Limited see short term momentumM&A Rumor & Fast Entry High Yield Stock Tips - Newser
VolitionRX (NYSEAMERICAN:VNRX) Share Price Passes Below 50-Day Moving AverageTime to Sell? - MarketBeat
VolitionRx : Short Corporate Deck, Sept 2025 - MarketScreener
VolitionRX (VNRX) Maintains "Buy" Rating with $5 Target Price | - GuruFocus
VolitionRx Partners with Werfen to Advance Diagnostic Testing for Antiphospholipid Syndrome - citybuzz -
VolitionRx (VNRX) Enters Agreement with Werfen for APS Research - GuruFocus
VolitionRx signs first human out licensing deal for APS - TipRanks
VolitionRx Limited stock momentum explained2025 Sector Review & AI Powered Market Entry Ideas - Newser
Volition Signs First Human Out Licensing Deal09.09.25News - Ariva
What institutional flow reveals about VolitionRx LimitedWeekly Profit Summary & Verified Entry Point Detection - Newser
Trend analysis for VolitionRx Limited this week2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
What’s next for VolitionRx Limited stock price2025 Technical Patterns & Intraday High Probability Alerts - Newser
What is VolitionRx Limited’s book value per shareJuly 2025 Sentiment & Stock Portfolio Risk Control - خودرو بانک
VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
What risks could impact VolitionRx Limited stock performance2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Veterinary Oncology Market Shares, Competition and Trends - GlobeNewswire
VolitionRx Limited stock prediction for this weekQuarterly Trade Summary & Verified Short-Term Plans - Newser
Will VolitionRx Limited outperform tech stocksLayoff News & Daily Chart Pattern Signals - خودرو بانک
Price momentum metrics for VolitionRx Limited explained2025 Performance Recap & Growth-Oriented Investment Plans - Newser
What technical models suggest about VolitionRx Limited’s comeback2025 Historical Comparison & Entry Point Strategy Guides - Newser
VolitionRx Ltd. Earnings Call: Key Insights and Challenges, Cost Reduction, Revenue Growth, and Promising Clinical Study Outcomes Amid Uncertainty - AInvest
Combining machine learning predictions for VolitionRx Limited2025 Top Gainers & Daily Price Action Insights - Newser
How to forecast VolitionRx Limited trends using time series2025 Technical Patterns & Risk Controlled Swing Alerts - Newser
VolitionRx : Corporate Presentation September 2025 - MarketScreener
Can VolitionRx Limited rally from current levels2025 AllTime Highs & Free Reliable Trade Execution Plans - Newser
Zacks Small Cap Weighs in on VolitionRx Q3 Earnings - MarketBeat
Developing predictive dashboards with VolitionRx Limited dataTrade Exit Summary & High Accuracy Trade Alerts - Newser
VolitionRx Ltd. Earnings Call: Key Insights and Challenges - TipRanks
Using AI based signals to follow VolitionRx Limited2025 Major Catalysts & High Conviction Trade Alerts - Newser
What earnings revisions data tells us about VolitionRx LimitedTrade Volume Report & Real-Time Volume Trigger Notifications - Newser
What to do if you’re stuck in VolitionRx LimitedMarket Performance Report & Stock Portfolio Risk Control - Newser
Tools to monitor VolitionRx Limited recovery probabilityLong Setup & Weekly Watchlist of Top Performers - Newser
Should I add VolitionRx Limited stock to my portfolioDollar Strength & Weekly Top Stock Performers List - 선데이타임즈
Analyzing drawdowns of VolitionRx Limited with statistical toolsTrade Volume Report & Low Risk Growth Stock Ideas - Newser
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):